By providing coverage for eligible patients, the policy helps reduce financial barriers to testing and expands access to innovative diagnostic technologies when deemed medically necessary by a health care professional.<\/p> The PrecivityAD2\u00ae blood test<\/a> aids health care professionals in determining the likelihood of amyloid plaques in the brain, one of the pathological hallmarks of Alzheimer\u2019s disease.<\/p> As the second-largest health insurer in the United States, Anthem\u00ae serves approximately 40 million medical members across 14 states, including California, the Midwest (Indiana, Missouri, Ohio, Wisconsin), the South (Georgia, Kentucky, Virginia), New England (Connecticut, Maine, New Hampshire), Colorado, Nevada, and parts of New York State.<\/p> Anthem highlighted the following in its medical policy decision<\/a>:<\/p> Dr. Joel Braunstein, President and CEO of C2N Diagnostics, said, \u201cThis is an important milestone for patients, families, and health care professionals. Anthem's coverage of the PrecivityAD2\u00ae blood test is a meaningful step toward reducing financial barriers and improving access to evidence-based, clinically validated Alzheimer's disease diagnostics. High-quality blood biomarker testing can facilitate timely evaluation through a minimally invasive, widely available approach. We appreciate Anthem for their policy and hope this decision encourages other private and public insurers to follow so that more people across the country can benefit from this diagnostic advance.\u201d<\/p> Dana Abendschein, a patient in Valley Park, Missouri who received the PrecivityAD2\u00ae test that helped his clinician confirm his Alzheimer\u2019s disease diagnosis, said, \u201cWith insurance coverage of diagnostics, we can help more patients receive an early and accurate diagnosis. I was able to get answers for my memory issues and then get on treatment. My goal is to keep doing the things I love to do for as long as I can do them.\u201d<\/p> The PrecivityAD2\u00ae test is available in all 50 states and the District of Columbia and can be ordered by a health care professional. Interested health care professionals can visit www.precivityad.com<\/a> or call 1.877.C2N.DIAG (226.3424) to learn more.<\/p> About C2N Diagnostics, LLC<\/b><\/p> C2N is a specialty diagnostics company with a vision to bring Clarity Through Innovation\u00ae. C2N strives to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. C2N\u2019s high-resolution mass spectrometry-based biomarker services and products are used for: clinical decision-making to improve patient care, including diagnosis and treatment monitoring; maximizing the quality and efficiency of clinical trials that test novel treatments for neurodegeneration; and providing innovative tools to help health care researchers better understand novel mechanisms of disease, identify new treatment targets, and conduct important epidemiologic studies to improve global public health. C2N assays have been used in over 200 Alzheimer\u2019s disease and other research studies throughout the U.S. and the world. This includes landmark treatment and prevention trials involving disease-modifying therapies (DMTs) that are changing the trajectory of Alzheimer\u2019s disease. C2N has ongoing collaborations with multi-national pharmaceutical and biotech companies, leading academic institutions, National Institute on Aging, Alzheimer\u2019s Association, and other non-profits and consortiums in addition to research and distribution partnerships with leading labs around the world including Grupo Fleury, Healius, Mediford, and Mayo Clinic Laboratories. Over 90,000 Precivity\u00ae-related biomarker measures have been reported through peer-reviewed publications, with many more manuscripts currently under review.<\/p> The company acknowledges generous support from National Institute on Aging, GHR Foundation, Alzheimer\u2019s Drug Discovery Foundation, BrightFocus Foundation, Alzheimer\u2019s Association and The Michael J. Fox Foundation. For more information, visit www.c2n.com<\/a>.<\/p> About the PrecivityAD2\u00ae Test<\/b><\/p> The PrecivityAD2\u00ae test is a clinically and analytically validated blood test used to assist in the evaluation of adult patients, aged 50 years and older, with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer\u2019s disease or other forms of cognitive decline. The PrecivityAD2\u00ae test uses immunoprecipitation followed by liquid chromatography-tandem mass spectrometry (LC-MS\/MS) to quantify \u03b2-Amyloid 1-42 (A\u03b242) and \u03b2-Amyloid 1-40 (A\u03b240) peptide concentrations, and phosphorylated and non-phosphorylated tau protein at amino acid threonine, position 217 (p-tau217 and np-tau217) peptide concentrations in human K2-EDTA plasma. A statistical algorithm combines the A\u03b242\/40 ratio and the p-tau217\/np-tau217 ratio x 100 (%p-tau217) to generate the Amyloid Probability Score 2 (APS2) result, a numeric value ranging from 0-100 to identify the likelihood of brain amyloid presence, a pathological hallmark of Alzheimer\u2019s disease. For more information, see www.precivity.com<\/a>.<\/p> C2N Diagnostics Contact: Medical policy marks a key commercial milestone as one of the nation’s largest insurers recognizes the clinical importance of Alzheimer’s blood biomarker testingST. LOUIS–(BUSINESS WIRE)–#Alzheimers–C2N Diagnostics, LLC (\u00ab\u00a0C2N\u00a0\u00bb), a specialty diagnost…<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-33926","post","type-post","status-publish","format-standard","hentry","category-infos-businesswire"],"_links":{"self":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/33926","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=33926"}],"version-history":[{"count":1,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/33926\/revisions"}],"predecessor-version":[{"id":33927,"href":"https:\/\/stocks-future.com\/index.php?rest_route=\/wp\/v2\/posts\/33926\/revisions\/33927"}],"wp:attachment":[{"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=33926"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=33926"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/stocks-future.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=33926"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}![](\"https:\/\/mms.businesswire.com\/media\/20260709196435\/en\/2848987\/22\/Logo.jpg\"){kind=logo}
<\/a>![](\"https:\/\/mms.businesswire.com\/media\/20260709196435\/en\/2848987\/21\/Logo.jpg\"){kind=logo}
<\/a>